Earlier in February, the New Delhi bench of the National Company Law Tribunal (NCLT) approved the amalgamation of Shree Jee ...

The move follows the approval from the National Company Law Tribunal (NCLT), New Delhi Bench. With this consolidation, the ...

Mankind Pharma has received a ₹183.11 crore tax demand from the Income Tax Department for AY 2014-15 to 2017-18 due to ...

IST, the barometer index, the S&P BSE Sensex, slipped 259.73 points or 0.34% to 77,348.12. The Nifty 50 index declined 66.35 points, or 0.28%, to 23,525.60.

Discover an intriguing stock idea with Mankind Pharma showing signs of a rebound and potential upside in price action.

U.S. President Trump imposes 25% tariff on auto imports, spotlight on pharma imports, Indian industry at risk.

Trump had earlier said on March 24 that he will announce tariffs on automobiles, pharmaceuticals and aluminum in the near ...

The Nifty Pharma index closed on a negative note on Wednesday. Shares of Mankind Pharma Ltd.(up 0.24 per cent), Biocon ...

AM(IST)on Monday in an upbeat market. Gland Pharma Ltd.(up 2.26 per cent), Laurus Labs Ltd.(up 2.02 per cent), J B Chemicals ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on MannKind (MNKD – Research Report) yesterday and set a price target of $9.00.

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...